BRIDGEWATER, N.J., June 14, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics, a leading provider of colorectal cancer testing and solutions, is pleased to announce that its CLIA licensed and CAP accredited New Jersey laboratory is now licensed by the State of California Department of Public Health to offer services for patients residing within the state of California. Clinical Genomics is the sole provider of COLVERA®, a liquid biopsy circulating tumor DNA (ctDNA) test used to detect minimal residual disease and recurrent disease in patients previously diagnosed with colorectal cancer.
Dr. Lawrence LaPointe, President and CEO of Clinical Genomics, said, “This approval allows California physicians to offer COLVERA to their patients in one of the largest oncology markets in the US and now the 5th largest economy in the world.”
“We are extremely pleased to make COLVERA available to colorectal cancer surgeons and medical oncologists in California where approximately 15,000 patients are newly diagnosed and treated for this disease each year, making up nearly 10% of all colorectal cancer cases in the United States,” added Dr. John P. Alsobrook II, DABCC, FACB, Laboratory Site Director and Vice President of Operations for Clinical Genomics Pathology.
About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, InSure® ONE™, a one sample FIT used to detect lower GI bleeding, and COLVERA®, a proprietary liquid biopsy blood test identifying circulating tumor DNA for detection of residual disease and early detection of recurrence in post-treatment patients. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.